Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Emerson Electric Co. (EMR) vs Nuwellis Inc (NUWE) Price & Performance

Emerson Electric Co.Trade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

Emerson Electric Co. vs Nuwellis Inc — how do they compare? Emerson Electric Co. trades at $161.65 (market cap $88.72B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Emerson Electric Co. is far larger — about 40327.3× Nuwellis Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Nuwellis Inc for 26 Days on average.

EMRNUWE
Market Cap
$88.72B$2.20M
Volume
2,355,255121,544
Sector
IndustrialsHealth
52-Week High
$164.38$146.65
52-Week Low
$123.30$0.68
Typical Hold Time
81 Days26 Days
Enterprise Value
$99.80B-$1.52M
Dividend Yield
1.4%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Emerson Electric Co.

Emerson Electric (EMR) trades at $161.13, up 1.2% today, with a bullish technical trend and strong quarterly earnings beats. The stock is supported by a 53.49% analyst buy consensus and a $165.90 price target. Revenue growth is steady, with 2025 revenue at $18.02B and net income of $2.29B, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. Recent news highlights momentum and Wall Street optimism, though valuation multiples like a P/E of 34.81 suggest premium pricing.

EMR's outlook is positive, driven by earnings momentum and analyst confidence, but risks include elevated valuation and debt levels. The stock offers growth potential with a dividend, yet investors face headwinds from competitive pressures and economic cycles. Upside to the consensus target implies modest gains, balancing fundamental strength with valuation concerns.

Nuwellis Inc

NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.

The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EMR
0% Buy100% Sell
Avg holding period · 81 Days
NUWE
2% Buy98% Sell
Avg holding period · 26 Days

Top news

Latest headlines on both assets

About Emerson Electric Co.

Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.

Read more on EMR →

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE →